Patricia Nasshorn - Feb 16, 2023 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
Chief Business Officer
Signature
/s/ Patricia Nasshorn by Kerri-Ann Millar, attorney-in-fact
Stock symbol
CUE
Transactions as of
Feb 16, 2023
Transactions value $
$0
Form type
4
Date filed
2/21/2023, 04:03 PM
Previous filing
Mar 29, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Stock Option (right to buy) Award $0 +97.9K $0.00 97.9K Feb 16, 2023 Common Stock 97.9K $3.21 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option becomes exercisable in eight equal semi-annual installments beginning on August 16, 2023.